SCHEMBL223943

SCHEMBL223943

c1cc(-c2ccccc2-c2cccc3[nH]c4ccccc4c23)nc(-c2ccccc2-c2cccc3[nH]c4ccccc4c23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.49
IMPDH1 P20839 1/20 0.49
CDK4 P11802 2/20 0.44
CCND1 P24385 2/20 0.44
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 2/20 0.43
GPR3 P46089 1/20 0.43
GABRP O00591 4/20 0.43
GABRD O14764 4/20 0.43
GABRA1 P14867 4/20 0.43
GABRB1 P18505 4/20 0.43
GABRG2 P18507 4/20 0.43
GABRB3 P28472 4/20 0.43
GABRA5 P31644 4/20 0.43
GABRA3 P34903 4/20 0.43
GABRA2 P47869 4/20 0.43
GABRB2 P47870 4/20 0.43
GABRA4 P48169 4/20 0.43
GABRE P78334 4/20 0.43
GABRA6 Q16445 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1326375 0.87 IMPDH2 (0.61) IMPDH2IMPDH1CDK4CCND1ALDH1A1
SCHEMBL866840 0.87 IMPDH2 (0.61) IMPDH2IMPDH1CDK4CCND1ALDH1A1
SCHEMBL26731069 0.87 IMPDH2 (0.61) IMPDH2IMPDH1CDK4CCND1ALDH1A1
SCHEMBL5933739 0.85 IMPDH2 (0.63) IMPDH2IMPDH1CDK4CCND1ALDH1A1
SCHEMBL21407081 0.79 IMPDH2 (0.52) IMPDH2IMPDH1CDK4CCND1ALDH1A1
SCHEMBL20261907 0.78 IMPDH2 (0.55) IMPDH2IMPDH1CDK4CCND1ALDH1A1
SCHEMBL25822165 0.77 BCHE (0.55) ALDH1A1HSD17B10GPR3GABRPGABRD
SCHEMBL24991458 0.76 KDM4E (0.43) IMPDH2IMPDH1CDK4CCND1ALDH1A1
SCHEMBL26731340 0.76 GABRA1 (0.49) IMPDH2IMPDH1CDK4CCND1ALDH1A1
Fluoranthene SCHEMBL28285154 0.76 ALDH1A1 (0.62) IMPDH2IMPDH1ALDH1A1HSD17B10GPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2416627-B1 ORGANIC ELECTROLUMINESCENT DEVICE NIPPON STEEL & SUMIKIN CHEM CO (JP) 2019-01-02 EP disclosed
US-9299947-B2 Organic electroluminescent device having an electron- and /or exciton-blocking layer comprising an indolocarbazole compound NIPPON STEEL & SUMIKIN CHEMICAL CO., LTD. (JP) 2016-03-29 US disclosed
US-8962158-B2 Material having indolocarbazole compound for phosphorescent light-emitting element and organic electroluminescent element using the same NIPPON STEEL & SUMIKIN CHEMICAL CO., LTD. (JP) 2015-02-24 US disclosed
EP-2416397-B1 MATERIAL FOR PHOSPHORESCENT LIGHT-EMITTING ELEMENT AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME NIPPON STEEL & SUMIKIN CHEM CO (JP) 2014-08-20 EP disclosed
EP-2416397-A1 MATERIAL FOR PHOSPHORESCENT LIGHT-EMITTING ELEMENT AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME Nippon Steel Chemical Co., Ltd. (JP) 2012-02-08 EP disclosed
EP-2416627-A1 ORGANIC ELECTROLUMINESCENT DEVICE Nippon Steel Chemical Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120007070-A1 ORGANIC ELECTROLUMINESCENT DEVICE NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) 2012-01-12 US disclosed
US-20120001165-A1 MATERIAL FOR PHOSPHORESCENT LIGHT-EMITTING ELEMENT AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120001165-A1 MATERIAL FOR PHOSPHORESCENT LIGHT-EMITTING ELEMENT AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME LEF1, ELOC, ELP1 IMPDH2 1596/4885IMPDH1 959/4885CDK4 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.